Abstract
The publication of the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) in 2013 raises important questions for clinical trials and associated regulatory decisions on new drugs for psychiatric disorders.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have